Cardiovascular burden of individuals diagnosed with idiopathic hypersomnia: Real-World Idiopathic Hypersomnia Total Health Model (CV-RHYTHM).

OBJECTIVE/

BACKGROUND

Limited research assesses cardiovascular risk in people with idiopathic hypersomnia. This study compared cardiovascular conditions or events among individuals with idiopathic hypersomnia with those among matched non-idiopathic hypersomnia controls.

PATIENTS/

METHODS

Claims from Merative™ MarketScan® Research Databases (12/2013-2/2020) were analyzed. Eligible individuals with idiopathic hypersomnia were ≥18 years of age upon cohort entry, continuously enrolled for 365 days before and after cohort entry (gaps ≤30 days allowed), and without cataplexy. Individuals with idiopathic hypersomnia entered the cohort upon their earliest medical claim with an idiopathic hypersomnia diagnosis code. Controls were matched 5:1, without replacement, to individuals with idiopathic hypersomnia using demographic characteristics. Odds of prevalent cardiovascular conditions or events during the 2-year assessment period (365 days before and after cohort entry date) were compared using unconditional logistic regression. Results were reported as odds ratios (ORs) with 95 % confidence intervals (CIs).

RESULTS

Final cohorts included 11,412 individuals with idiopathic hypersomnia and 57,058 matched controls. Odds (OR, 95 % CI) of cardiovascular disease (2.26, 2.14-2.38), major adverse cardiovascular event (2.08, 1.89-2.30), stroke (2.07, 1.87-2.29), hypertension diagnosis or antihypertensive use (2.02, 1.93-2.12), heart failure (1.97, 1.76-2.20), atrial fibrillation (1.91, 1.66-2.20), myocardial infarction (1.74, 1.42-2.12), and coronary revascularization (1.58, 1.12-2.17) were higher in individuals with idiopathic hypersomnia than matched controls.

CONCLUSIONS

Individuals with idiopathic hypersomnia had higher odds of prevalent cardiovascular conditions or events than matched controls. These results reinforce that clinicians should be aware of patients' cardiovascular risk profiles when selecting idiopathic hypersomnia treatments.